financetom
Business
financetom
/
Business
/
What's Going On With Longeveron Stock?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
What's Going On With Longeveron Stock?
Jun 13, 2024 10:31 AM

Longeveron Inc. ( LGVN ) shares are trading higher Thursday, and the stock is up more than 200% this week. Here's a look at what's going on. 

What To Know:

Longeveron ( LGVN ) shares climbed more than 150% Wednesday after Zacks Small Cap Research issued a report on the company with a $15.10 price valuation.

Longeveron ( LGVN ) signed its first contract for its advanced manufacturing facility in early June, which is expected to generate between $4 million and $5 million in annual revenue.

The company also announced a successful meeting with investigators in its ongoing Phase 2b clinical trial for Lomecel-B on Tuesday and said the trial is on track to complete enrollment by the end of 2024.

Longeveron ( LGVN ) shares are moving on heavy trading volume with more than 135 million shares already changing hands in Thursday session, according to data from Benzinga Pro. 

Related News: Virgin Galactic’s Board Approves Reverse Stock Split: What’s Going On With The Stock?

Should I Sell My LGVN Stock?

When deciding to hold on to or sell a stock, investors should consider their time horizon, unrealized gains and total return.

Shares of Longeveron ( LGVN ) have decreased by 89.55% in the past year. An investor who bought shares of Longeveron ( LGVN ) at the beginning of the year would take a loss of $9.50 per share if they sold it today. The stock has risen 176.11% over the past month, meaning an investor who bought shares on May 1 would see a capital gain of $1.89.

Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Longeveron ( LGVN ) stock currently has an RSI of 79.94, indicating overbought conditions.

For access to advanced charting and analysis tools and stock data, check out Benzinga PRO. Try it for free.

LGVN Price Action: According to Benzinga Pro, Longeveron ( LGVN ) shares are up 70.7% at $3.09 at the time of publication Thursday.

Image: Shutterstock

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Barrick Gold Reports Higher Q2 Adjusted Net Earnings, to Pay Dividend
Barrick Gold Reports Higher Q2 Adjusted Net Earnings, to Pay Dividend
Aug 12, 2024
06:50 AM EDT, 08/12/2024 (MT Newswires) -- Barrick Gold ( GOLD ) on Monday reported an increase in adjusted net earnings in the second quarter despite lower gold and copper production. Second-quarter adjusted net earnings came in at US$557 million, or US$0.32 per share, up from US$336 million, or US$0.19 per share. The result beat the S&P Capital IQ consensus...
Scotiabank to Buy 15% Stake in KeyCorp for US$2.8 Billion
Scotiabank to Buy 15% Stake in KeyCorp for US$2.8 Billion
Aug 12, 2024
06:48 AM EDT, 08/12/2024 (MT Newswires) -- Scotiabank (BNS.TO, BNS), one of Canada's biggest banks, agreed to buy almost 15% of KeyCorp, a U.S.-based financial services company, for about US$2.8 billion. Scotiabank will pay $17.17 per KeyCorp share, an 11% premium to the average price over the last 20 trading days, the Canadian bank said in a statement. KeyCorp operates...
Japan's SMBC has raised stake in Jefferies Financial to nearly 11%
Japan's SMBC has raised stake in Jefferies Financial to nearly 11%
Aug 12, 2024
NEW YORK, Aug 12 (Reuters) - Jefferies Financial Group ( JEF ) said on Monday that Japan's Sumitomo Mitsui Banking Corp (SMBC) has more than doubled its stake in the U.S. investment bank to 10.9%, deepening an alliance dating back to 2021. As part of the expanded ties, Toru Nakashima, the CEO of Sumitomo Mitsui Financial Group ( SMFG ),...
Pfizer's RSV vaccine shows benefit in immuno-compromised adults in study
Pfizer's RSV vaccine shows benefit in immuno-compromised adults in study
Aug 12, 2024
Aug 12 (Reuters) - Pfizer ( PFE ) said on Monday its respiratory syncytial virus (RSV) vaccine Abrysvo generated a strong immune response in a late-stage study of four groups of adults aged 18 and older with a compromised immune system. A single 120 microgram dose of the vaccine generated strong neutralizing antibodies against both subtypes of RSV, called RSV-A...
Copyright 2023-2026 - www.financetom.com All Rights Reserved